Hemispherx to Present at the 30th Annual ROTH Conference
March 05, 2018 08:30 ET
|
Hemispherx Biopharma, Inc.
ORLANDO, Fla., March 05, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB), focused on pharmaceutical research, announced today that it will be presenting at the 30th Annual...
Hemispherx to Present at the Inaugural LD Micro Virtual Conference
February 27, 2018 08:30 ET
|
Hemispherx Biopharma, Inc.
ORLANDO, Fla., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB), focused on pharmaceutical research, announced today that it will be presenting at the inaugural LD...
Hemispherx To Supply Ampligen for Pancreatic Cancer Patients in Canada Under Special Access Program
February 26, 2018 08:30 ET
|
Hemispherx Biopharma, Inc.
ORLANDO, Fla., Feb. 26, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB) said it is expanding its partnership with myTomorrows to supply Ampligen® for pancreatic cancer...
Hemispherx’s Ampligen Highlighted in Review of Role of TLR3 Agonist Support for “Universal” Flu Immunization Development Programs
January 31, 2018 08:30 ET
|
Hemispherx Biopharma, Inc.
BANFF, Alberta, Jan. 31, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB) said William Mitchell, MD, PhD*, Professor of Pathology, Microbiology & Immunology at Vanderbilt...
Hemispherx to Present at the BIO CEO & Investor Conference
January 29, 2018 08:30 ET
|
Hemispherx Biopharma, Inc.
ORLANDO, Fla., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB), focused on pharmaceutical research, announced today that it will be presenting at the BIO CEO &...
Hemispherx Announces Presentation on the Potential Role of Ampligen as an Immune System Amplifier Improving Seasonal Flu Vaccine Cross-Protection
January 26, 2018 08:30 ET
|
Hemispherx Biopharma, Inc.
ORLANDO, Fla., Jan. 26, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB), focused on pharmaceutical research, announces that William Mitchell, MD, PhD, Professor of Pathology,...
Hemispherx Announces Data Presentation on the Potential for Ampligen to Improve Cancer Outcomes with Checkpoint Inhibitors
January 25, 2018 08:30 ET
|
Hemispherx Biopharma, Inc.
MIAMI, Jan. 25, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB), focused on pharmaceutical research, announced that Pawel Kalinski, MD, vice chairman for translational...
Hemispherx Comments on $500+ Million Market Opportunity for Ampligen®, the Only Late Stage ME/CFS Candidate in the U.S.
January 23, 2018 08:30 ET
|
Hemispherx Biopharma, Inc.
ORLANDO, Fla., Jan. 23, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB), focused on pharmaceutical research, today commented on the overall market opportunity for its...
Hemispherx Enters into Sale/Leaseback Agreement for NJ Development and Production Facility
January 17, 2018 08:30 ET
|
Hemispherx Biopharma, Inc.
ORLANDO, Fla., Jan. 17, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB), focused on pharmaceutical research, today said it has entered into a sale and leaseback agreement for...
Hemispherx Enhances Manufacturing Efficiency of Ampligen
January 11, 2018 08:30 ET
|
Hemispherx Biopharma, Inc.
ORLANDO, Fla., Jan. 11, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB), has successfully tested a new chemical catalyst used in the manufacturing process of Ampligen®, a...